Clinical Significance of P53, C-MYC and BCL-6 Abnormality in Patients with Diffuse Large B Cell Lymphoma.
- Author:
Cheng-Guo CHAI
1
;
Jian-Jun ZHANG
2
;
Ning LI
3
;
Lei CAO
4
;
Shuang-Yang ZHANG
5
Author Information
- Publication Type:Journal Article
- MeSH: DNA-Binding Proteins; genetics; metabolism; Humans; In Situ Hybridization, Fluorescence; Lymphoma, Large B-Cell, Diffuse; diagnosis; genetics; metabolism; Prognosis; Proto-Oncogene Proteins c-bcl-6; Proto-Oncogene Proteins c-myc; genetics; metabolism; Tumor Suppressor Protein p53; genetics; metabolism
- From: Journal of Experimental Hematology 2016;24(1):89-93
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo study the clinical significance of P53, C-MYC and BCL-6 abnormality in the patients with diffuse large B cell lymphoma (DLBCL).
METHODSFrom July 2011 to January 2013, 80 patients with DLBCL were admitted in our hospital and were chosen as study objects, their clinical data were collected. The abnormality of P53, C-MYC and BCL-6 was examined by using I-FISH for all the patients. The correlation of abnormality of P53, C-MYC and BCL-6 with clinical staging, curative efficacy and prognosis of the patients were analyzed.
RESULTSOut of 80 patients 27 patients (33.75%) had P53 deletion, 24 patients (30.00%) had C-MYC rearrangement/amplification, and 46 patients (57.50%) had BCL-6 rearrangement. The P53 deletion, C-MYC rearrangement/amplification and BCL-6 rearrangement significantly correlated with staging, curative effect and prognosis of the patients (P < 0.05).
CONCLUSIONThe curative efficacy and prognosis of the DLBCL patients with abnormality of P53, C-MYC and BCL-6 have been confirmed to be unsatisfactory.
